Reproductive Endocrinology Practice Questions

Q: A 24-year-old nulliparous woman presents with secondary amenorrhea for 6 months. She is a competitive marathon runner training 70 miles per week with 12% body fat. Labs show: LH 1.2 mIU/mL (normal follicular phase: 2-10), FSH 2.1 mIU/mL (normal: 3-10), estradiol 15 pg/mL (normal follicular: 30-100), prolactin 14 ng/mL (normal: <25), TSH 2.1 mIU/L. Apply these findings to determine the mechanism of her amenorrhea.

Hypothalamic amenorrhea from energy deficit and low leptin. ***Hypothalamic amenorrhea from energy deficit and low leptin*** - This clinical scenario describes **functional hypothalamic amenorrhea (FHA)**, where excessive exercise and low body fat lead to suppressed **GnRH pulsatility** and low levels of **LH, FSH, and estradiol**. - Chronic energy deficit and decreased adipose tissue result in low **leptin levels**, which signals the hypothalamus to downregulate the reproductive axis to conserve energy. *Primary ovarian insufficiency from autoimmune destruction* - This condition presents with **hypergonadotropic hypogonadism**, characterized by **elevated FSH** and LH levels due to lack of negative feedback from the ovaries. - The patient has **low-normal gonadotropins**, which rules out ovarian failure or premature depletion of follicles. *Polycystic ovary syndrome with LH/FSH ratio abnormality* - PCOS typically presents with **hyperandrogenism** (e.g., hirsutism, acne) and an **increased LH/FSH ratio**, rather than the low levels seen here. - Patients with PCOS are more likely to exhibit **menstrual irregularities** or oligomenorrhea associated with insulin resistance rather than exercise-induced hypothalamic suppression. *Pituitary adenoma causing hyperprolactinemia* - A prolactinoma would cause **elevated prolactin** levels, which inhibit GnRH secretion, but this patient's prolactin is within the **normal range**. - Pituitary causes are also usually associated with other symptoms like headaches or **visual field defects** if the tumor is a macroadenoma. *Asherman syndrome from endometrial adhesions* - This diagnosis is unlikely in a **nulliparous woman** without a history of uterine instrumentation or intrauterine infection. - Patients with Asherman syndrome have normal hormone levels (**ovulatory cycles**) because the pathology is structural (uterine) rather than hormonal (hypothalamic-pituitary).

Q: Testicular feminization syndrome is characterized by all of the following except?

Presence of Barr body. **Explanation:** **Testicular Feminization Syndrome (now known as Complete Androgen Insensitivity Syndrome - CAIS)** is a condition where a genetic male (46, XY) has a total resistance to androgens due to a defect in the androgen receptor. **Why Option D is the Correct Answer:** The **Barr body** represents an inactivated X chromosome, typically found in individuals with more than one X chromosome (e.g., 46, XX females or 47, XXY males). Since CAIS patients have a **46, XY genotype**, they possess only one X chromosome, which remains active. Therefore, they are **Barr body negative**. **Analysis of Other Options:** * **A. Absent uterus:** In these patients, the testes are present (usually intra-abdominal) and secrete **Anti-Müllerian Hormone (AMH)**. AMH causes the regression of Müllerian structures, leading to the absence of the uterus, fallopian tubes, and upper third of the vagina. * **B. Primary amenorrhea:** Due to the absence of a uterus and ovaries, these patients typically present during puberty with a failure to start menstruation. * **C. Normal breast development:** Peripheral conversion of testosterone to estrogen (aromatization) occurs. Since there is no androgen action to oppose this estrogen, patients develop normal, often feminine, breast contours (though the nipples/areolae may be pale). **High-Yield Clinical Pearls for NEET-PG:** * **Karyotype:** 46, XY (Genetically male, Phenotypically female). * **Gonads:** Testes (Risk of gonadoblastoma; gonadectomy is recommended after puberty/attainment of height). * **Hair:** Characteristically **absent or scanty** axillary and pubic hair (due to androgen resistance). * **Vagina:** Blind-ending pouch (short vagina). * **Differential Diagnosis:** **Müllerian Agenesis (MRKH Syndrome)**. Distinguishing factor: MRKH has a 46, XX karyotype, normal pubic hair, and normal ovaries.

Q: A female presents with normal breast development but scanty pubic hair. What is the most likely diagnosis?

Testicular feminizing syndrome. **Explanation:** The clinical presentation of **normal breast development** paired with **scanty or absent pubic/axillary hair** is a classic hallmark of **Androgen Insensitivity Syndrome (AIS)**, historically known as **Testicular Feminizing Syndrome**. **1. Why the Correct Answer is Right:** In AIS, the individual has a **46, XY** karyotype and functioning testes that produce testosterone. However, due to a defect in androgen receptors, the body cannot respond to testosterone. * **Breast Development:** Occurs because the high levels of testosterone are peripherally converted to estrogen (aromatization). * **Scanty Pubic Hair:** Pubic and axillary hair growth is dependent on androgens. Since the receptors are non-functional, hair growth is minimal or absent. * **Anatomy:** MIF (Müllerian Inhibiting Factor) is produced, so there is no uterus or fallopian tubes (blind-ending vagina). **2. Why Incorrect Options are Wrong:** * **Turner’s Syndrome (45, XO):** Characterized by "streak gonads" and low estrogen. Patients typically present with **primary amenorrhea and absent breast development** (sexual infantilism). * **Müllerian Agenesis (MRKH Syndrome):** These patients are **46, XX** with normal ovaries. They have **normal breast development AND normal pubic hair** (since androgen receptors are functional), but lack a uterus and upper vagina. * **Gonadal Dysgenesis:** Similar to Turner’s, the lack of functional gonads leads to estrogen deficiency, resulting in a lack of secondary sexual characteristics (no breast development). **High-Yield Clinical Pearls for NEET-PG:** * **Karyotype:** AIS is 46, XY; MRKH is 46, XX. * **Gonads:** In AIS, testes are often found in the inguinal canal or abdomen (risk of gonadoblastoma; requires removal after puberty). * **Differential Diagnosis:** The presence or absence of pubic hair is the most important clinical differentiator between AIS (absent) and MRKH (present).

Q: Which of the following tests can differentiate Mullerian agenesis (MRKH syndrome) from complete androgen insensitivity syndrome (testicular feminization syndrome)?

Karyotyping. **Explanation:** Both **Mullerian Agenesis (MRKH Syndrome)** and **Complete Androgen Insensitivity Syndrome (CAIS)** present with primary amenorrhea, a blind vaginal pouch, and well-developed breasts. However, their underlying genetic and hormonal profiles are fundamentally different. **Why Karyotyping is the Correct Answer:** Karyotyping is the definitive diagnostic tool to differentiate these two conditions. * **MRKH Syndrome:** Patients are genetically female (**46, XX**). They have normal ovaries and female-range testosterone levels. * **CAIS:** Patients are genetically male (**46, XY**). They have undescended testes and male-range testosterone levels, but appear phenotypically female because their tissues are unresponsive to androgens. **Analysis of Incorrect Options:** * **A & B (3D Ultrasound/MRI):** While both imaging modalities are excellent for identifying the absence of a uterus and cervix, they cannot reliably distinguish between a 46,XX individual (MRKH) and a 46,XY individual (CAIS) based solely on pelvic anatomy, as both lack Mullerian structures. * **D (Serum Testosterone):** While testosterone levels are significantly higher in CAIS (male range) than in MRKH (female range), **Karyotyping** remains the gold standard for definitive diagnosis and is the preferred initial step in the workup of primary amenorrhea with absent internal organs. **High-Yield Clinical Pearls for NEET-PG:** 1. **Pubic/Axillary Hair:** This is the most important clinical differentiator. It is **normal** in MRKH but **absent or scanty** in CAIS (due to androgen resistance). 2. **Gonads:** In MRKH, ovaries are present (normal ovulation/hormones). In CAIS, testes are present (usually intra-abdominal or inguinal). 3. **Management:** In CAIS, the gonads must be removed (gonadectomy) after puberty to prevent malignancy (gonadoblastoma/dysgerminoma). In MRKH, the focus is on vaginal creation (dilatation or vaginoplasty).

Q: A female presents with primary amenorrhea and absent vagina. What is the next investigation to be done?

Laparoscopy. **Explanation:** The clinical presentation of primary amenorrhea with an absent vagina primarily points towards two major differentials: **Müllerian Agenesis (MRKH Syndrome)** and **Androgen Insensitivity Syndrome (AIS)**. **Why Laparoscopy is the correct answer:** In the context of this specific question, **Laparoscopy** is considered the definitive investigation to visualize the internal pelvic anatomy. It allows for the direct confirmation of the presence or absence of the uterus, fallopian tubes, and ovaries. In Müllerian Agenesis, laparoscopy would typically reveal a rudimentary uterus (bicornuate bulbs) with normal ovaries, whereas in AIS, the uterus is absent and gonads are undescended testes. While MRI is a non-invasive alternative often used in modern practice, laparoscopy remains the "gold standard" for anatomical confirmation in surgical planning and diagnostic dilemmas in competitive exams. **Analysis of Incorrect Options:** * **A. LH/FSH assay:** These are useful for diagnosing hypogonadotropic hypogonadism or premature ovarian failure, but they do not help in evaluating anatomical defects like an absent vagina. * **B. Chromosomal analysis:** While essential to differentiate MRKH (46,XX) from AIS (46,XY), it is usually performed after anatomical confirmation or as a secondary step. * **C. Urinalysis:** This has no diagnostic value for primary amenorrhea or Müllerian anomalies. **High-Yield Clinical Pearls for NEET-PG:** * **Müllerian Agenesis (MRKH):** Most common cause of primary amenorrhea with absent vagina. Characterized by 46,XX karyotype, normal ovaries, and normal secondary sexual characters. * **Associated Anomalies:** Always check for **Renal anomalies** (most common, e.g., renal agenesis) and skeletal defects (VACTERL) in cases of MRKH. * **AIS:** Characterized by 46,XY karyotype, absent/scant pubic hair, and presence of testes (risk of gonadoblastoma).

Q: A young female presented with primary amenorrhea. Examination reveals normal breast development and absent axillary hairs. Pelvic examination shows a normally developed vagina with clitoromegaly. On ultrasound, gonads are visible in the inguinal region. What is the most likely diagnosis?

Partial androgen insensitivity syndrome. **Explanation:** The clinical presentation hinges on the spectrum of **Androgen Insensitivity Syndrome (AIS)**, an X-linked recessive condition where a 46,XY individual has a functional defect in androgen receptors. **Why Partial AIS (PAIS) is correct:** In PAIS, there is partial responsiveness to androgens. The presence of **clitoromegaly** (ambiguous genitalia) and **axillary hair** (though often sparse, its presence or the virilization of genitalia distinguishes it from the "Complete" form) are hallmark signs. The patient has normal breast development due to the peripheral conversion of testosterone to estrogen. The presence of **inguinal gonads** (testes) and a short/blind-ending vagina (due to Anti-Müllerian Hormone production by testes) confirms the diagnosis. **Why other options are incorrect:** * **Complete AIS (CAIS):** Presents with a purely female phenotype. There is **no clitoromegaly** and characteristically **absent or very scanty** axillary/pubic hair. * **MRKH Syndrome:** These are 46,XX individuals with normal ovaries. They would have **normal axillary/pubic hair** (normal adrenarche) and no clitoromegaly or inguinal testes. * **Gonadal Dysgenesis (e.g., Turner Syndrome):** Typically presents with **absent breast development** (due to ovarian failure/streak gonads) and elevated gonadotropins. **High-Yield Clinical Pearls for NEET-PG:** * **Karyotype:** Both CAIS and PAIS are **46,XY**. * **The "Hair" Rule:** CAIS = Hairless (absent axillary/pubic hair); MRKH = Hairy (normal hair). * **Management:** In AIS, gonads are removed after puberty (to allow natural height gain and breast development) to prevent **gonadoblastoma/dysgerminoma**, followed by estrogen replacement. * **Differential:** If a patient has primary amenorrhea, absent uterus, but **normal male-range testosterone**, think AIS. If testosterone is in the **female range**, think MRKH.

Q: A 21-year-old female presents with primary amenorrhea, absent breast development, and cubitus valgus. What is the most probable diagnosis?

Turner's syndrome. **Explanation:** The clinical triad of **primary amenorrhea**, **absent secondary sexual characteristics** (no breast development), and **skeletal deformities** (cubitus valgus) is a classic presentation of **Turner’s Syndrome (45,XO)**. 1. **Why Turner’s Syndrome is correct:** In Turner’s syndrome, accelerated atresia of germ cells leads to **streak ovaries**. The resulting lack of estrogen causes a failure of breast development (Tanner Stage 1) and primary amenorrhea. Cubitus valgus (increased carrying angle of the elbow) is a characteristic skeletal stigmata of this condition, along with short stature and webbed neck. 2. **Why the other options are incorrect:** * **MRKH Syndrome:** These patients have a 46,XX karyotype with normal ovarian function. Therefore, they have **normal breast development** and secondary sexual characteristics, despite having primary amenorrhea due to Müllerian agenesis. * **Androgen Insensitivity Syndrome (AIS):** These patients (46,XY) have **well-developed breasts** (due to peripheral conversion of testosterone to estrogen) but lack pubic/axillary hair and have a blind-ending vagina. * **Mixed Gonadal Dysgenesis:** While it can present with short stature, it typically presents with **ambiguous genitalia** and a mosaic karyotype (45,X/46,XY), which is not described here. **High-Yield Clinical Pearls for NEET-PG:** * **Most common karyotype:** 45,XO (50%). * **Most common cardiac lesion:** Bicuspid aortic valve (overall); Coarctation of aorta (classic association). * **Most common renal anomaly:** Horseshoe kidney. * **Hormonal Profile:** Hypergonadotropic hypogonadism (High FSH/LH, Low Estrogen). * **Management:** Growth hormone for stature; Estrogen/Progesterone for secondary sexual characteristics and bone health.

Q: Anti-Müllerian Hormone is:

An indicator that indirectly reflects the primordial follicle pool.. ### Explanation **Correct Answer: B. An indicator that indirectly reflects the primordial follicle pool.** **Why it is correct:** Anti-Müllerian Hormone (AMH) is a member of the TGF-β superfamily. It is secreted by the **granulosa cells** of pre-antral and small antral follicles (up to 8mm). Since the number of these growing follicles is proportional to the total number of dormant primordial follicles remaining in the ovary, AMH serves as a highly reliable **indirect biochemical marker of the ovarian reserve.** **Analysis of Incorrect Options:** * **Option A:** AMH is a **glycoprotein**, not a glycolipid. While it is secreted by granulosa cells, its production begins in primary follicles and is highest in pre-antral and small antral stages. * **Option C:** AMH levels **decrease** as a woman ages and become undetectable or nearly zero during the menopausal transition, reflecting the exhaustion of the oocyte pool. * **Option D:** In females, AMH is secreted by the ovaries (granulosa cells). In males, it is secreted by the **Sertoli cells** of the testes to cause regression of the Müllerian ducts during fetal development. It is not secreted by the Müllerian ducts themselves. **High-Yield Clinical Pearls for NEET-PG:** * **Cycle Independence:** Unlike FSH, AMH levels remain relatively constant throughout the menstrual cycle, allowing it to be tested on any day. * **PCOS:** AMH levels are characteristically **elevated** in Polycystic Ovary Syndrome due to the high number of small antral follicles. * **Best Marker:** AMH is considered the most sensitive marker for ovarian reserve and is used to predict response to controlled ovarian stimulation in IVF. * **Early Marker:** It is the first marker to show a decline in the aging ovary, preceding changes in FSH or Inhibin B.

Q: Which of the following is the best diagnostic method for confirming ovulation?

Endometrial biopsy. **Explanation:** The correct answer is **Endometrial biopsy**. While several methods can suggest ovulation, an endometrial biopsy is traditionally considered the "gold standard" for confirming that ovulation has occurred and that the corpus luteum is producing adequate progesterone. **1. Why Endometrial Biopsy is Correct:** Ovulation is followed by the formation of the corpus luteum, which secretes **progesterone**. Progesterone induces specific **secretory changes** in the endometrium. Performing a biopsy during the mid-luteal phase (typically day 21-23 of a 28-day cycle) and finding secretory endometrium provides definitive histological proof that the ovary has been exposed to progesterone, thus confirming prior ovulation. **2. Why Other Options are Incorrect:** * **A. Ultrasound:** Serial transvaginal sonography (Folliculometry) is excellent for monitoring follicular growth and disappearance (suggesting rupture), but it is an indirect visualization and cannot confirm the functional hormonal status as accurately as histology. * **B. Laparoscopy:** While it can visualize a *corpus hemorrhagicum* or a stigma on the ovary, it is an invasive surgical procedure and not a routine diagnostic tool for confirming ovulation. * **D. Chromotubation:** This is a procedure performed during laparoscopy to check for **tubal patency** using methylene blue dye; it has no role in assessing ovulation. **NEET-PG High-Yield Pearls:** * **Most accurate single-day test:** Serum Progesterone levels >3 ng/ml (measured on Day 21) are the most common clinical method to confirm ovulation. * **Luteal Phase Defect (LPD):** Diagnosed if the endometrial dating lags by more than 2 days behind the actual menstrual day. * **Spinnbarkeit Effect:** Refers to the elasticity of cervical mucus under estrogen influence (pre-ovulatory); this disappears after ovulation due to progesterone.

Question 1

A 24-year-old nulliparous woman presents with secondary amenorrhea for 6 months. She is a competitive marathon runner training 70 miles per week with 12% body fat. Labs show: LH 1.2 mIU/mL (normal follicular phase: 2-10), FSH 2.1 mIU/mL (normal: 3-10), estradiol 15 pg/mL (normal follicular: 30-100), prolactin 14 ng/mL (normal: <25), TSH 2.1 mIU/L. Apply these findings to determine the mechanism of her amenorrhea.

Accepted Answer

Hypothalamic amenorrhea from energy deficit and low leptin

Answer

Primary ovarian insufficiency from autoimmune destruction

Answer

Polycystic ovary syndrome with LH/FSH ratio abnormality

Answer

Pituitary adenoma causing hyperprolactinemia

Answer

Asherman syndrome from endometrial adhesions

Question 2

Testicular feminization syndrome is characterized by all of the following except?

Accepted Answer

Presence of Barr body

Answer

Absent uterus

Answer

Primary amenorrhea

Answer

Normal breast development

Question 3

A female presents with normal breast development but scanty pubic hair. What is the most likely diagnosis?

Accepted Answer

Testicular feminizing syndrome

Answer

Turner's syndrome

Answer

Mullerian agenesis

Answer

Gonadal dysgenesis

Question 4

Which of the following tests can differentiate Mullerian agenesis (MRKH syndrome) from complete androgen insensitivity syndrome (testicular feminization syndrome)?

Accepted Answer

Karyotyping

Answer

3D Ultrasound

Answer

MRI

Answer

Serum testosterone levels

Question 5

A female presents with primary amenorrhea and absent vagina. What is the next investigation to be done?

Accepted Answer

Laparoscopy

Answer

LH/FSH assay

Answer

Chromosomal analysis

Answer

Urinalysis

Question 6

A young female presented with primary amenorrhea. Examination reveals normal breast development and absent axillary hairs. Pelvic examination shows a normally developed vagina with clitoromegaly. On ultrasound, gonads are visible in the inguinal region. What is the most likely diagnosis?

Accepted Answer

Partial androgen insensitivity syndrome

Answer

Complete androgen insensitivity syndrome

Answer

Mayer Rokitansky Kuster Hauser syndrome

Answer

Gonadal dysgenesis

Question 7

A 21-year-old female presents with primary amenorrhea, absent breast development, and cubitus valgus. What is the most probable diagnosis?

Accepted Answer

Turner's syndrome

Answer

Mixed gonadal dysgenesis

Answer

Mayer Rokitansky Kuster Hauser syndrome

Answer

Androgen insensitivity syndrome

Question 8

Which of the following hormones stimulates increased testosterone production by ovaries in PCOD?

Accepted Answer

Luteinizing Hormone

Answer

Estrogen

Answer

Follicle-stimulating Hormone

Answer

Inhibin

Question 9

Anti-Müllerian Hormone is:

Accepted Answer

An indicator that indirectly reflects the primordial follicle pool.

Answer

A glycolipid secreted by granulosa cells of the secondary follicle.

Answer

A hormone that increases progressively across the menopausal transition.

Answer

A hormone secreted by Müllerian duct derivatives.

Question 10

Which of the following is the best diagnostic method for confirming ovulation?

Accepted Answer

Endometrial biopsy

Answer

Ultrasound

Answer

Laparoscopy

Answer

Chromotubation

Reproductive Endocrinology — MCQs

Reproductive Endocrinology — MCQs

On this page

Practice by Chapter

Want unlimited practice?